XORTX Therapeutics Inc. – TSX:XRTX.V

XORTX Therapeutics stock price today

CAD 0.76
-0.91
-54.76%
Financial Health
0
1
2
3
4
5
6
7
8
9

XORTX Therapeutics stock price monthly change

-37.08%
month

XORTX Therapeutics stock price quarterly change

-37.08%
quarter

XORTX Therapeutics stock price yearly change

-41.87%
year

XORTX Therapeutics key metrics

Market Cap
 6.11M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 -1.54
Revenue
 N/A
EBITDA
 -6.78M
Income
 -3.34M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

XORTX Therapeutics stock price history

XORTX Therapeutics stock forecast

XORTX Therapeutics financial statements

Profit Margin

XORTX Therapeutics Inc. (TSX:XRTX.V): Profit margin
Jun 2023 0 -1.69M
Sep 2023 0 -1.33M
Dec 2023 0 2.69M
Mar 2024 0 -3.01M
XRTX.V income statement history

XORTX Therapeutics Financials Estimate

XORTX Therapeutics Inc. (TSX:XRTX.V): Analyst Estimates
Mar 2024 0 -3.01M
Sep 2025 0 -765.55K
Dec 2025 0 -593.69K
Dec 2025 0 -732.27K

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

XORTX Therapeutics Inc. (TSX:XRTX.V): Debt to assets
Jun 2023 7801168 403.26K 5.17%
Sep 2023 6640147 553.75K 8.34%
Dec 2023 5467964 825.93K 15.11%
Mar 2024 6050598 3.55M 58.83%
XRTX.V balance sheet history

Cash Flow

XORTX Therapeutics Inc. (TSX:XRTX.V): Cash Flow
Jun 2023 -1.73M -9.53K -8.76K
Sep 2023 -1.07M -7.29K -16.67K
Dec 2023 -1.29M -9.79K -312.25K
Mar 2024 -1.30M -2.62K 1.70M
XRTX.V cash flow history

XORTX Therapeutics alternative data

XORTX Therapeutics
Employees

XORTX Therapeutics Inc. (TSX:XRTX.V): Employee count
Aug 2023 3
Sep 2023 3
Oct 2023 3
Nov 2023 3
Dec 2023 3
Jan 2024 3
Feb 2024 3
Mar 2024 3
Apr 2024 3
May 2024 2
Jun 2024 2
Jul 2024 2

XORTX Therapeutics other data

Frequently Asked Questions (FAQ)

  • What's the price of XORTX Therapeutics stock today?

    One share of XORTX Therapeutics stock can currently be purchased for approximately $0.76.

  • When is XORTX Therapeutics's next earnings date?

    Unfortunately, XORTX Therapeutics's (XRTX.V) next earnings date is currently unknown.

  • Does XORTX Therapeutics pay dividends?

    No, XORTX Therapeutics does not pay dividends.

  • How much money does XORTX Therapeutics make?

    XORTX Therapeutics has a market capitalization of 6.11M.

  • What is XORTX Therapeutics's stock symbol?

    XORTX Therapeutics Inc. is traded on the TSX under the ticker symbol "XRTX.V".

  • What is XORTX Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of XORTX Therapeutics?

    Shares of XORTX Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does XORTX Therapeutics have?

    As Jul 2024, XORTX Therapeutics employs 2 workers, which is 33% less then previous quarter.

  • When XORTX Therapeutics went public?

    XORTX Therapeutics Inc. is publicly traded company for more then 3 years since IPO on 5 Nov 2021.

  • What is XORTX Therapeutics's official website?

    The official website for XORTX Therapeutics is xortx.com.

  • Where are XORTX Therapeutics's headquarters?

    XORTX Therapeutics is headquartered at 421 – 7th Avenue SW, Vancouver, BC.

  • How can i contact XORTX Therapeutics?

    XORTX Therapeutics's mailing address is 421 – 7th Avenue SW, Vancouver, BC.

XORTX Therapeutics company profile:

XORTX Therapeutics Inc.

xortx.com
Exchange:

TSX

Full time employees:

3

Industry:

Biotechnology

Sector:

Healthcare

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

421 – 7th Avenue SW
Vancouver, BC T2P 4K9

:
ISIN: CA98420Q3061
: